Research is being conducted on the use of circulating tumor dna (ctdna) and liquid biopsies in breast cancer care, with potential applications including predicting treatment response and monitoring minimal residual disease. These diagnostic tools may help transform breast cancer care, although some outlets suggest a need to navigate hype and consider future perspectives. The development of increasingly specific ctdna assays and other new diagnostic tools is seen as key to advancing breast oncology.